Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
22.53
-0.45 (-1.96%)
Nov 5, 2025, 9:56 AM EST - Market open
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SYRE News
- 17 hours ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 hours ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 12 days ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 20 days ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - GlobeNewsWire
- 22 days ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire
- 22 days ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire
- 6 weeks ago - Intelligent Development Could Make Spyre Therapeutics Best In Show - Seeking Alpha